Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Chief R&D Officer | April 06, 2026 | April 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date April 06, 2026 · Filed April 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 205,150 |
Reported balance
After 2026-04-06 transaction · row 1
1 source rowRow 1 · 2026-04-06 · Grant · Acquired 205,150 · Balance 205,150 F1: Inducement grant of restricted stock units pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated (the "Stock Incentive Plan"), which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. |
| Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.47 · Expires 2036-04-06 | Direct | 441,350 |
Reported balance
After 2026-04-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-06 · Grant · Acquired 441,350 · Balance 441,350 F2: Inducement grant of employee stock options pursuant to the Stock Incentive Plan, which will become exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Inducement grant of restricted stock units pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated (the "Stock Incentive Plan"), which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
F2: Inducement grant of employee stock options pursuant to the Stock Incentive Plan, which will become exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 06, 2026 Filed Apr 7, 2026 20:24 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 441,350 | $0.00 Strike: $9.47 | $0.00 |
DisclosureSEC source: 0000882796-26-000019 · form4.xml · derivative · entry 2 Menon Sandeep · CIK 0002123967 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 441,350 Underlying: Common Stock · 441,350 shares Expires 2036-04-06 F2 · shares: Inducement grant of employee stock options pursuant to the Stock Incentive Plan, which will become exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. F2 · derivative.exercise_date: Inducement grant of employee stock options pursuant to the Stock Incentive Plan, which will become exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 20:24 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 205,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000882796-26-000019 · form4.xml · nonDerivative · entry 1 Menon Sandeep · CIK 0002123967 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,150 F1 · shares: Inducement grant of restricted stock units pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated (the "Stock Incentive Plan"), which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.